Pharma BD Deal Intelligence
The Quebec plant became a long-term pillar of GSK's flu/pandemic vaccine supply chain, but a multi-year FDA/Health Canada quality crisis (2011-2014) undercut the operational story.
Full analysis, sources & comparables →GSK pays $1.4B (CDN$35/share, ~CDN$1.7B) for ID Biomedical, betting on flu vaccine capacity expansion and pandemic preparedness positioning.
GSK CEO Jean-Pierre Garnier said the company would manufacture 150 million doses of seasonal flu vaccine a year by the end of the decade. Acquisition timed to…
FDA approved FluLaval as fifth licensed US seasonal flu vaccine ten months after deal close - validating the acquisition thesis by adding meaningful US supply…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK announces $1.4B acquisition of ID Biomedical (CDN$35/share, ~CDN$1.7B) plus $77M debt assumption. Gains Fluviral and influenza vaccine pipeline. Closed Dec 8, 2005.
The Quebec plant became a long-term pillar of GSK's flu/pandemic vaccine supply chain, but a multi-year FDA/Health Canada quality crisis (2011-2014) undercut the operational story.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / ID Biomedical Corporation (this deal) | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
| GlaxoSmithKline plc / Reliant Pharmaceuticals Inc. | 2007 | $1.6B | 47 |
← Browse all deals · How we score deals
More: 2005 deals · GlaxoSmithKline plc deals